权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Improved long-term biocompatibility of coronary stents by plasma coating process

通过等离子涂层工艺改善冠状动脉支架的长期生物相容性

基本信息

批准号：
9301988
负责人：
Meng Chen
金额：
$ 93.83万
依托单位：
NANOVA, INC.
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-01 至 2020-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9301988
关键词：
Acute Acute myocardial infarction Adhesions American Ammonia Animals Arterial Fatty Streak Arteries Atherosclerosis Autopsy Benign Biological Availability Blood Platelets Blood coagulation Body Fluids Cardiac Cell Proliferation Cessation of life Clinical Clinical Trials Coronary Coronary Vessels Coronary artery Coronary heart disease Corrosion Defibrillators Deposition Endothelium Enrollment Evaluation Family suidae Fibrin Funding Generations Goals Healthcare Immobilization Impaired wound healing Injury Intervention Knowledge Lead Lesion Measurable Medical Device Metals Miniature Swine Modeling Myocardial Infarction National Heart, Lung, and Blood Institute Nitric Oxide Oryctolagus cuniculus Outcome Oxygen Pacemakers Patients Pharmaceutical Preparations Phase Physiologic pulse Plasma Process Recovery Recurrence Research Project Grants Resistance Risk Safety Silicon Small Business Innovation Research Grant Smooth Muscle Smooth Muscle Myocytes Stainless Steel Stents Surface System Technology Testing Thinness Tissues Toxic effect United States Vascular Endothelium base biomaterial compatibility cold temperature commercialization covalent bond cytotoxicity effective therapy functional group genotoxicity healing high risk iliac artery implantation improved in vitro testing innovation irritation man monomer nanocoating nanoscale non-drug novel prevent programs research and development restenosis sensor stent thrombosis

项目摘要

Improved long-term biocompatibility of coronary stents by plasma coating process Abstract Drug-eluting stents (DES) have been widely used to treat patients of coronary heart disease (CHD) due to their better ability to control restenosis than bare metal stents (BMS). However, there is a high risk of late in-stent thrombosis associated with DES after implantation in patients, which could lead to fatal heart attack and death even though it occurs at low rate. Thus, for safe and effective clinical use, a coronary stent needs to have better long-term biocompatibility on its surface that will provide sufficient thrombo-resistance in addition to inhibiting smooth muscle cell proliferation thereby slowing down healing of tissues around the stent. Nanova, Inc. is developing a novel coating layer of high thrombo-resistance on the surface of stents made of stainless steel or CrCo. An environmentally benign technology, low temperature plasma process is used to deposit an ultra-thin (nano-scale) but continuous layer of coating, sufficient to generate desired abrasion resistance and immobilize the bioactive functional groups created in the subsequent surface treatment to prevent blood clotting and restenosis, but thin enough to allow for stent expansion without cracking when delivered into the atherosclerotic coronary arteries of patients. The knowledge gained in this innovative research project will also benefit research and development for improved biocompatibility for other implantable medical devices such as pacemakers, pulse generators, cardiac defibrillators and bio-sensors.

等离子涂层工艺改善冠状动脉支架的长期生物相容性